Meet Prostate Cancer Surgeon James Eastham
Meet Prostate Cancer Surgeon James Eastham
James A. Eastham, MD, FACS
Urologic Surgeon
Titles
Chief, Urology Service; Peter T. Scardino Chair in Oncology
Clinical Expertise
Prostate Cancer; Nerve-Sparing Techniques; Salvage Radical Prostatectomy; Robotic Prostatectomy
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Eastham accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 646-422-4390 Office Phone
- Speaks English

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, University of Southern California, Los Angeles
Residencies
Urology - Los Angeles County - University of Southern California Medical Center
Fellowships
Urologic Oncology - Baylor College of Medicine
Board Certifications
Urology
I am a surgeon who specializes in nerve-sparing radical prostatectomy for the treatment of prostate cancer and salvage radical prostatectomy in patients with prostate cancer in whom radiation therapy has failed.
I completed my fellowship in urologic oncology in 1995 and have been in practice since then, devoting the past 15 years exclusively to the care of men with prostate cancer.
Read more
I see about 300 men with prostate cancer each year. Many of them have low-risk disease and are candidates for active surveillance, meaning that no immediate treatment is necessary. In this approach, we monitor the tumor closely for signs that it might be growing or becoming more aggressive and hold off on treatment. For those men with more high-risk cancer that requires treatment, I primarily perform robotic-assisted radical prostatectomy.
At MSK, our treatment recommendations are based on personal risk. Not all men have the same risk — one size does not fit all. Many prostate cancers are of such low risk that treatment would only result in possible side effects, without improving patients’ life expectancy. Such cancers are best managed with active surveillance. Other men will benefit from either surgery or radiation therapy.
While most men are candidates for robotic surgery, some may still do better with traditional open surgery, a procedure I also perform. An area of special interest to me is men with high-risk prostate cancer who might not have been considered candidates for traditional open surgery. This includes men who have previously been treated with radiation therapy but whose cancer has returned.
My clinical research focuses on improving outcomes following surgery for prostate cancer. This includes controlling the cancer and restoring normal urinary and sexual function. Together with my colleagues in medical oncology and radiation oncology, we tailor therapy as accurately as possible to each individual’s cancer to control or cure it while minimizing treatment-related side effects.
We’re also starting to investigate the role of local treatment — surgery or radiation — in selected men with low-volume metastatic prostate cancer, meaning that their cancer has spread to a limited number of other sites in the body. Such men have traditionally been treated only with hormonal therapy. We are now investigating using a therapy in which men receive systemic treatment, such as chemotherapy, plus local treatment. The goal is to prolong survival and, ultimately, cure the cancer.
In addition, certain carefully selected men may be candidates for focal therapy, in which just the area of the prostate with the cancer is treated rather than the entire gland. This approach reduces the risk of treatment side effects while still eradicating the cancer.
During the course of my career I’ve given more than 180 invited presentations at meetings and symposia in the United States and around the world. I have also published 300 peer-reviewed studies in prestigious national and international journals.
As a doctor, my focus is on the whole person, not just his disease. I want my patients to be alive, but also to be able to live full and enjoyable lives.
As a doctor, my focus is on the whole person, not just his disease.
-Dr. Eastham
Awards and Honors
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2010-2020)
- Phi Beta Kappa
- Alpha Omega Alpha
- National Kidney Foundation Research Fellowship Award
- American Cancer Society Clinical Fellowship Award
- Lamar Fleming Award-Gene Therapy in Prostate Cancer
- Patients’ Choice: Rated & Awarded by Patients
- Best Clinical Paper Published in European Urology in 2011: “Salvage Radical Prostatectomy for Radiation-Recurrent Prostate Cancer: A Multi-institutional Collaboration”
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Eastham
- A Phase I Study of Photodynamic Therapy in People with Recurrent Prostate Cancer
- Clinical Trials Co-Investigated by Dr. Eastham
- A Study of Multi-Modality Therapy for Very High-Risk Localized and Low-Volume Prostate Cancer

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Books and Book Chapters
“Salvage radical prostatectomy for recurrence of prostate cancer after radiation therapy.” Eastham JA, Scardino PT. In: Comprehensive Textbook of Genitourinary Oncology. 3rd ed. Vogelzang NJ, Scardino PT, Shipley WU, DF Coffey, eds. Baltimore: Lippincott Williams and Wilkins; 2006: 306-314.
“Nerve-sparing radical retropubic prostatectomy.” Eastham JA, Jarrard DF. In: Atlas of the Prostate. 3rd ed. Scardino PT, Slawin KM, eds. Philadelphia: Current Medicine; 2006: 145-161.
“Preservation of sexual function after treatment for prostate cancer.” Eastham JA. In: Prostate Cancer: Principles and Practice. Kirby RS, Partin AW, Feneley M, Parsons JK, eds. Abington, UK: Taylor & Francis; 2006: 675-682.
“Expectant management of prostate cancer.” Eastham JA, Scardino PT. In: Campbell’s Urology. 9th ed. Kavoussi LR, Novick AC, Partin AW, Wein AJ, eds. Philadelphia: WB Saunders; 2007.
“Cancer of the prostate.” Zelefsky MJ, Eastham JA, Sartor AO. In: DeVita, Hellman, and Rosenberg’s: Cancer Principles & Practice of Oncology. DeVita VT Jr., Lawrence TS, Rosenberg SA, eds. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011: 1220-1279.
Visit PubMed for a full listing of Dr. Eastham’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James A. Eastham discloses the following relationships and financial interests:
-
3D Biopsy
Ownership / Equity Interests
-
Simulated Inanimate Models, LLC
Ownership / Equity Interests
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].